Current process and future path for health economic assessment of pharmaceuticals in France

Mondher Toumi (1) , Cécile Rémuzat (2) , Emna El Hammi (3) , Aurélie Millier (2) , Samuel Aballéa (2) , Christos Chouaid (4) , Bruno Falissard (5)

1 Laboratoire de Santé Publique
2 Creativ-Ceutical
3 Evidenz
4 BCR - Biomécanique cellulaire et respiratoire
5 UMR_S 669 - Troubles du comportement alimentaire de l'adolescent

The Social Security Funding Law for 2012 introduced the Economic and Public Health Assessment Committee (Commission Evaluation Economique et de Santé Publique, or CEESP) in the Social Security Code as a specialised committee affiliated with the Haute Autorité de Santé in charge of providing recommendations and health economic opinions. This article provides an in-depth description of the CEESP's structure and working methods, and analyses the impact of health economic assessment on market access of drugs in France. It also points out the areas of uncertainty and the conflicting rules following the introduction of the health economic assessment in France. The authors also provide their personal opinion on the likely future of health economic assessment of drugs in France, including the possible merge of the CEESP and the Transparency Committee, the implementation of a French threshold, and the extension of health economic assessment to a larger number of products.

Mots clés: health economic assessment; CEESP; HAS; France; market access; cost-effectiveness

Domaines: Santé publique et épidémiologie; Economies et finances

Mondher Toumi, Cécile Rémuzat, Emna El Hammi, Aurélie Millier, Samuel Aballéa, et al.. Current process and future path for health economic assessment of pharmaceuticals in France. Journal of Market Access & Health Policy, 2015, 3 (1), pp.27902. ⟨10.3402/jmahp.v3.27902⟩. ⟨hal-01772997⟩